Rubbish Check
Daily Mail Money · 3 August 2026
source“Astra takes £18bn hit as merger talks get a thumbs down: Analysts ‘perplexed’ by £300bn tie-up with US rival”
R3/ 10
Lightly altered
Rubbish Rating — 1 = base fact, 10 = pure rubbish
12345678910
In short
Rubbish Talk rates the Daily Mail's claim that AstraZeneca shares tumbled and analysts were "perplexed" by a £300bn Bristol Myers Squibb tie-up a 3/10, because every core figure (the 9% share drop, the near-£300bn/$400bn combined valuation, and the "perplexed" quote) is independently corroborated, with the only spin being that unconfirmed early-stage talks are framed as a firmer "tie-up" than the reporting actually supports.
The Verdict
Lightly altered. The numbers check out against multiple outlets, but the headline's confident "tie-up" framing glosses over the fact that neither company confirmed the merger talks and a deal may never materialise.
What actually happened
AstraZeneca shares fell sharply after the Financial Times reported the company had held preliminary talks with US rival Bristol Myers Squibb about a mega-merger. Neither firm confirmed the report, and the drop reflected investor unease about the rationale for a deal, not a completed transaction. Jefferies analyst Michael Leuchten was among those who publicly questioned the logic, using the word "perplexed."
Key facts
- Shares fell as much as 9% on the day, matching the article's cited move from 1132p to 11,500p; Reuters separately described the fall as the biggest one-day drop since 2020.
- A combined AstraZeneca-BMS entity would be valued at roughly $400bn, which converts to the article's cited £300bn figure, a conversion consistent with other outlets' reporting.
- The "perplexed" reaction traces to a specific Jefferies analyst quote: Leuchten said the rationale for combining was "not yet clear" and that he was "a bit perplexed" given Astra's own growth profile, a framing also picked up in CNBC's own headline.
- Neither AstraZeneca nor Bristol Myers Squibb confirmed the talks; sources told Reuters and Bloomberg a deal may not be reached, a caveat the Mail includes in its body copy but not its headline.
- Soriot had told markets just days earlier that Astra did not "need mergers and acquisitions" to hit its 2030 sales target, an inconsistency the article notes but buries mid-story.
What to watch for
Watch whether AstraZeneca or BMS issues any formal confirmation or denial in the coming days, since the entire story currently rests on unconfirmed reporting. If talks quietly die, outlets that ran firm "merger" framing (rather than "reported talks") will look overstated in hindsight; if Soriot pushes ahead as the article suggests, the regulatory and political friction flagged by Jefferies becomes the next storyline to track.
About this scoreThe R-Score is Rubbish Talk's editorial opinion on how far a headline's framing sits from what the underlying facts support. It is a judgement about presentation and emphasis, not an allegation that any outlet has acted dishonestly. Every figure we rely on is linked under Receipts so you can check it yourself.
Related
